EDT Nektar (NKTR) files $300M mixed securities shelfLight Up your Portfolio with Spark:Easily identify stocks' risks and opportunities.

The interleukin-2 (IL-2) therapies market in the USA is poised for major growth, projected to reach $4 billion by 2034, ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a ...

We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil. In this article, we are going ...

SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William Blair in a research note issued to investors on Thursday,RTT News reports.

Fintel reports that on March 14, 2025, Oppenheimer upgraded their outlook for Nektar Therapeutics (NasdaqCM:NKTR) from Perform to Outperform. Analyst Price Forecast Suggests 418.64% Upside As of ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 EPS, expectations were $-0.13. Operator: Good day, and thank you for ...